WallStSmart

Abbott Laboratories (ABT)vsEnovis Corp (ENOV)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 1928% more annual revenue ($46.59B vs $2.30B). ABT leads profitability with a 11.7% profit margin vs -48.0%. ENOV appears more attractively valued with a PEG of 1.90. ENOV earns a higher WallStSmart Score of 55/100 (C).

ABT

Buy

54

out of 100

Grade: C-

Growth: 4.0Profit: 6.0Value: 3.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

ENOV

Buy

55

out of 100

Grade: C

Growth: 7.3Profit: 3.0Value: 6.3Quality: 5.0
Piotroski: 4/9Altman Z: -0.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-37.5%)

Margin of Safety

-37.5%

Fair Value

$74.13

Current Price

$101.95

$27.82 premium

UndervaluedFair: $74.13Overvalued
ENOVUndervalued (+34.6%)

Margin of Safety

+34.6%

Fair Value

$34.86

Current Price

$19.28

$15.58 discount

UndervaluedFair: $34.86Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$176.41B9/10

Large-cap with strong market position

Free Cash FlowQuality
$2.09B8/10

Generating 2.1B in free cash flow

ENOV2 strengths · Avg: 10.0/10
Price/BookValuation
0.8x10/10

Reasonable price relative to book value

EPS GrowthGrowth
153.1%10/10

Earnings expanding 153.1% YoY

Areas to Watch

ABT3 concerns · Avg: 3.3/10
PEG RatioValuation
1.904/10

Expensive relative to growth rate

P/E RatioValuation
33.4x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-47.5%2/10

Earnings declined 47.5%

ENOV4 concerns · Avg: 3.5/10
PEG RatioValuation
1.904/10

Expensive relative to growth rate

Revenue GrowthGrowth
3.2%4/10

3.2% revenue growth

Market CapQuality
$1.07B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
4.2%3/10

Operating margin of 4.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Free Cash Flow. Revenue growth of 13.0% demonstrates continued momentum.

Bull Case : ENOV

The strongest argument for ENOV centers on Price/Book, EPS Growth.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.

Bear Case : ENOV

The primary concerns for ENOV are PEG Ratio, Revenue Growth, Market Cap.

Key Dynamics to Monitor

ABT profiles as a value stock while ENOV is a turnaround play — different risk/reward profiles.

ENOV carries more volatility with a beta of 1.43 — expect wider price swings.

ABT is growing revenue faster at 13.0% — sustainability is the question.

ABT generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

ENOV scores higher overall (55/100 vs 54/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Enovis Corp

HEALTHCARE · MEDICAL DEVICES · USA

Enovis Corporation is a global medical technology company. The company is headquartered in Wilmington, Delaware.

Want to dig deeper into these stocks?